REG - Societe Generale SA Takeda Pharma.Co.Ltd - Form 8.3 - Takeda Pharmaceutical CO LTD (AMENDED)
15/08/2018 14:10
For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20180814:nRSN9187Xa
RNS Number : 9187X
Societe Generale SA
15 August 2018
FORM 8.3
Replacement Form 8.3. to amend sections2.(a) and TOTAL Interests positions and
section 3.(a)
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Full name of discloser: Société Générale S.A.
(b) Owner or controller of interests and short positions disclosed, if
different from 1(a):
The naming of nominee or vehicle companies is insufficient. For a
trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form Takeda Pharmaceutical CO LTD
relates:
Use a separate form for each offeror/offeree
(d) If an exempt fund manager connected with an offeror/offeree, state this
and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken: 13/08/2018
For an opening position disclosure, state the latest practicable date
prior to the disclosure
(f) In addition to the company in 1(c) above, is the discloser making YES: Shire PLC
disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one
class of relevant securities of the offeror or offeree named in 1(c), copy
table 2(a) or (b) (as appropriate) for each additional class of relevant
security.
(a) Interests and short positions in the relevant securities of
the offeror or offeree to which the disclosure relates following the dealing
(if any)
Class of relevant security: Ordinary
Interests Short positions
Number % Number %
(1) Relevant securities owned and/or controlled: 2,594,572 0.33 5,958,406 0.76
(2) Cash-settled derivatives: 4,693,017 0.60 5,026 0.00
(3) Stock-settled derivatives (including options) and agreements to 121,500 0.02 0 0.00
purchase/sell:
7,409,089 0.94 5,963,432 0.76
TOTAL:
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded
options), or agreements to purchase or sell relevant securities, should be
given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors'
and other employee options)
Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities
of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as
appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security Purchase/sale Number of securities Price per unit
JPY
Ordinary Purchase 2,500 4640
Ordinary Purchase 200 4706
Ordinary Purchase 200 4695
Ordinary Purchase 400 4701.5
Ordinary Purchase 100 4638
Ordinary Purchase 100 4638
Ordinary Purchase 100 4644.5
Ordinary Purchase 100 4646
Ordinary Purchase 100 4705.5
Ordinary Purchase 100 4688.5
Ordinary Purchase 200 4695
Ordinary Purchase 100 4672.5
Ordinary Purchase 100 4670.5
Ordinary Purchase 100 4649.5
Ordinary Purchase 100 4649.5
Ordinary Purchase 200 4682
Ordinary Purchase 100 4682
Ordinary Purchase 200 4676.5
Ordinary Purchase 100 4678
Ordinary Purchase 100 4676.5
Ordinary Purchase 100 4639.5
Ordinary Purchase 100 4670
Ordinary Purchase 100 4682.5
Ordinary Purchase 100 4664.5
Ordinary Purchase 100 4664.5
Ordinary Purchase 2,000 4675
Ordinary Purchase 700 4640
Ordinary Purchase 500 4640
Ordinary Purchase 600 4683
Ordinary Purchase 100 4684
Ordinary Purchase 1,000 4665
Ordinary Purchase 1,000 4644
Ordinary Purchase 1,000 4704
Ordinary Purchase 1,000 4643
Ordinary Purchase 500 4690
Ordinary Purchase 2,000 4678
Ordinary Purchase 200 4644
Ordinary Purchase 600 4701
Ordinary Purchase 100 4701
Ordinary Purchase 300 4702
Ordinary Purchase 400 4703
Ordinary Purchase 800 4711
Ordinary Purchase 1,000 4698
Ordinary Purchase 300 4712
Ordinary Purchase 1,000 4696
Ordinary Purchase 700 4695
Ordinary Purchase 500 4639
Ordinary Purchase 900 4638
Ordinary Purchase 600 4650
Ordinary Purchase 100 4639
Ordinary Purchase 1,000 4678
Ordinary Purchase 600 4706
Ordinary Purchase 1,000 4704
Ordinary Purchase 1,000 4703
Ordinary Purchase 1,500 4704
Ordinary Purchase 600 4640
Ordinary Purchase 500 4698
Ordinary Purchase 100 4645
Ordinary Purchase 200 4646
Ordinary Purchase 400 4704
Ordinary Purchase 200 4685
Ordinary Purchase 300 4704
Ordinary Purchase 300 4638
Ordinary Purchase 100 4643
Ordinary Purchase 600 4695
Ordinary Purchase 2,900 4640
Ordinary Purchase 12,900 4677
Ordinary Purchase 200 4703
Ordinary Purchase 200 4661
Ordinary Purchase 200 4646
Ordinary Purchase 200 4647
Ordinary Purchase 12,900 4640
Ordinary Purchase 100 4674
Ordinary Purchase 100 4700
Ordinary Purchase 100 4667
Ordinary Purchase 100 4642
Ordinary Purchase 100 4643
Ordinary Purchase 100 4646
Ordinary Purchase 702,782 4692
Ordinary Purchase 100 4677
Ordinary Purchase 84 4692
Ordinary Sale 100 4651
Ordinary Sale 600 4698
Ordinary Sale 700 4648
Ordinary Sale 100 4646
Ordinary Sale 500 4642
Ordinary Sale 100 4643
Ordinary Sale 400 4642
Ordinary Sale 300 4643
Ordinary Sale 900 4708
Ordinary Sale 1,200 4641
Ordinary Sale 200 4644
Ordinary Sale 100 4641
Ordinary Sale 700 4651
Ordinary Sale 200 4645
Ordinary Sale 2,200 4640
Ordinary Sale 1,200 4642
Ordinary Sale 200 4644
Ordinary Sale 300 4642
Ordinary Sale 2,200 4638
Ordinary Sale 600 4674
Ordinary Sale 1,100 4701
Ordinary Sale 800 4643
Ordinary Sale 100 4703
Ordinary Sale 100 4705
Ordinary Sale 100 4638
Ordinary Sale 900 4645
Ordinary Sale 500 4704
Ordinary Sale 800 4698
Ordinary Sale 1,000 4697
Ordinary Sale 600 4701
Ordinary Sale 400 4702
Ordinary Sale 300 4700
Ordinary Sale 800 4699
Ordinary Sale 400 4703
Ordinary Sale 300 4707
Ordinary Sale 100 4709
Ordinary Sale 300 4712
Ordinary Sale 200 4711
Ordinary Sale 400 4660
Ordinary Sale 1,300 4715
Ordinary Sale 200 4714
Ordinary Sale 1,200 4711
Ordinary Sale 400 4700
Ordinary Sale 100 4705
Ordinary Sale 200 4702
Ordinary Sale 800 4700
Ordinary Sale 100 4659
Ordinary Sale 1,100 4659
Ordinary Sale 300 4675
Ordinary Sale 1,900 4637
Ordinary Sale 200 4708
Ordinary Sale 2,200 4642
Ordinary Sale 400 4684
Ordinary Sale 1,000 4710
Ordinary Sale 200 4643
Ordinary Sale 300 4644
Ordinary Sale 1,600 4679
Ordinary Sale 1,100 4708
Ordinary Sale 100 4644
Ordinary Sale 400 4650
Ordinary Sale 600 4702
Ordinary Sale 500 4703
Ordinary Sale 100 4645
Ordinary Sale 400 4705
Ordinary Sale 1,800 4686
Ordinary Sale 400 4698
Ordinary Sale 100 4640
Ordinary Sale 200 4640
Ordinary Sale 800 4708
Ordinary Sale 900 4708
Ordinary Sale 300 4643
Ordinary Sale 100 4642
Ordinary Sale 100 4691
Ordinary Sale 1,500 4698
Ordinary Sale 500 4645
Ordinary Sale 100 4645
Ordinary Sale 1,000 4665
Ordinary Sale 500 4647
Ordinary Sale 1,000 4680
Ordinary Sale 700 4673
Ordinary Sale 700 4699
Ordinary Sale 800 4675
Ordinary Sale 1,000 4648
Ordinary Sale 400 4646
Ordinary Sale 2,000 4643
Ordinary Sale 1,000 4681
Ordinary Sale 200 4667
Ordinary Sale 300 4703
Ordinary Sale 14,000 4640
Ordinary Sale 12,900 4677
Ordinary Sale 1,000 4640
Ordinary Sale 200 4677
Ordinary Sale 100 4664
Ordinary Sale 300 4664
Ordinary Sale 400 4644
Ordinary Sale 400 4644
Ordinary Sale 400 4673
Total Purchases 765,066
Total Sales 84,800
(b) Cash-settled derivative transactions
Class of relevant security Product description Nature of dealing Number of reference securities Price per unit JPY
e.g. CFD e.g. opening/closing a long/short position, increasing/reducing a long/short
position
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type Expiry date Option money paid/ received per unit JPY
e.g. American, European etc.
(ii) Exercise
Class of relevant security Product description Exercising/ exercised against Number of securities Exercise price per unit JPY
e.g. call option
(d) Other dealings (including subscribing for new securities)
Class of relevant security Nature of dealing Details Price per unit (if applicable) JPY
e.g. subscription, conversion
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or
understanding, formal or informal, relating to relevant securities which may
be an inducement to deal or refrain from dealing entered into by the person
making the disclosure and any party to the offer or any person acting in
concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If
there are no such agreements, arrangements or understandings, state "none"
(b) Agreements, arrangements or understandings relating to
options or derivatives
Details of any agreement, arrangement or understanding, formal or informal,
between the person making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant
securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached? YES
Date of disclosure: 15/08/2018
Contact name: Olivier Vero
Telephone number: +44 20 7676 6969
Public disclosures under Rule 8 of the Code must be made to a Regulatory
Information Service.
The Panel's Market Surveillance Unit is available for consultation in relation
to the Code's disclosure requirements on +44 (0)20 7638 0129.The Code can be
viewed on the Panel's website at www.thetakeoverpanel.org.uk
SUPPLEMENTAL FORM 8 (OPEN POSITIONS)
DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING OPTION) POSITIONS,
AGREEMENTS TO PURCHASE OR SELL ETC.
Note 5(i) on Rule 8 of the Takeover Code (the "Code")
1. KEY INFORMATION
Full name of person making disclosure: SOCIETE GENERALE SA
Name of offeror/offeree in relation to whose relevant securities the Takeda Pharmaceutical CO LTD
disclosure relates:
2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)
Class of relevant security Product description e.g. call option Written or purchased Number of securities to which option or derivative relates Exercise price per unit Type Expiry date
JPY e.g. American, European etc.
Ordinary OTC put-option Sale 15,700 4707 European options 14/12/2018
Ordinary OTC put-option Sale 30,000 5075.10 European options 14/12/2018
Ordinary OTC put-option Sale 29,600 5073.65 European options 14/12/2018
Ordinary OTC put-option Sale 15,500 4491.40 European options 14/12/2018
Ordinary OTC put-option Sale 30,700 4533.90 European options 14/12/2018
3. AGREEMENTS TO PURCHASE OR SELL ETC.
Full details should be given so that the nature of the interest or position
can be fully understood:
It is not necessary to provide details on a Supplemental Form (Open Positions)
with regard to cash-settled derivatives.
The currency of all prices and other monetary amounts should be stated.
The Panel's Market Surveillance Unit is available for consultation in relation
to the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk
(http://www.thetakeoverpanel.org.uk) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
Recent news on Takeda Pharmaceutical Co
See all newsREG - Malin Corp PLC - Malin Announces 2021 Full Year Results
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Confirmation of post-offer intention statements
AnnouncementREG - Morgan Stanley&CoLLC Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI) - Replacement of Takeda
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Statement re Applicable Exchange Rate
AnnouncementREG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - Replacement of Takeda
Announcement